Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Targovax
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Targovax
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Targovax
Deal Size : $100.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Targovax
Deal Size : $100.0 million
Deal Type : Licensing Agreement
Reset All
